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TRANSDERMAL DELIVERY OF OPIOID 
ANTAGONIST PRODRUGS 
BACKGROUND OF THE INVENTION 
1. Technical Field 
The present invention relates to a composition, a method 
and an apparatus for transdermally delivering an effective 
amount of opioid antagonists derived from prodrugs for 
treatment of eating disorders, narcotic dependence and alco 
holism. Alternatively, the present invention relates to a 
composition, a method and an apparatus for transdermally 
delivering an effective amount of an opioid antagonist 
derived from pro-drugs and an effective amount of an opioid 
agonist for treatment of pain. 
2. Related Art 
Opioid antagonists such as NaltreXone may be used for 
treatment of narcotic dependence and alcoholism. NaltreX 
one is currently available as NaltreXone Hydrochloride in a 
50-mg oral tablet (ReVia®). 
There is a need to accurately deliver effective amounts of 
opioid antagonists such as NaltreXone in a manner that 
encourages voluntary compliance When such opioid antago 
nists are used for the treatment of narcotic dependence and 
alcoholism. 
SUMMARY OF THE INVENTION 
The present invention provides a composition, a method 
and an apparatus for transdermally delivering an effective 
amount of opioid antagonists derived from prodrugs for 
treatment of narcotic dependence and alcoholism. In 
addition, the present invention relates to a composition, a 
method and an apparatus for transdermally delivering an 
effective amount of an opioid antagonist derived from 
prodrugs and an effective amount of an opioid agonist for 
treatment of pain. 
BRIEF DESCRIPTION OF THE DRAWINGS 
FIG. 1 depicts a front cross-sectional vieW of a transder 
mal drug delivery apparatus on a substrate, in accordance 
With preferred embodiments of the present invention. 
FIG. 2 depicts FIG. 1 after an impermeable barrier has 
been formed in the transdermal drug delivery apparatus. 
FIG. 3 is a graph shoWing NTX and Valeroyl-NTX 
accumulation over time as measured in vitro. 
FIG. 4 is a bar graph shoWing the effect of age, seX or 
condition of skin sample (fresh or froZen) on NTX ?uX. 
FIG. 5 is a bar graph shoWing the lag time in ?uX for 
NTX, Valeroyl-NTX and Hep-NTX. 
DETAILED DESCRIPTION OF THE 
INVENTION 
The present invention relates to an apparatus, a method 
and a composition for transdermally delivering an effective 
amount of opioid antagonists derived from prodrugs for 
treatment of narcotic dependence and alcoholism. 
Hereinafter, the term “effective amount” is an optimal trans 
dermally delivered dose of prodrug, determined by one 
skilled in the art, needed for treating narcotic dependence 
and alcoholism. Also hereinafter, the term “transdermally 
delivering or delivery” means applying and affixing a skin 
permeable prodrug to the skin, Wherein the prodrug under 
goes physiological hydrolysis, resulting in introducing the 
hydrolyZed prodrug into the systemic circulatory system of 
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a mammal. Also, hereinafter, the term “physiological 
hydrolysis or physiologically hydrolyZable, or physiologi 
cally hydrolyZing” means replacement of R, or R and R1 in 
prodrugs infra With a hydrogen atom as the prodrug 
passes through the skin. In addition, hereinafter, the term 
“opioid antagonist” refers to various substances that are able 
to block the receptors for opiates and thus prevent the 
euphoric effects of, eg morphine and alcohol. Furthermore, 
hereinafter the term “prodrug” refers to a drug that has been 
chemically modi?ed by substitution of an R or R1 group as 
in the prodrugs infra. 
The apparatus for transdermal delivery comprises: a pro 
drug permeable adhesive layer having a ?rst surface and a 
second surface on a substrate; a prodrug layer, having an 
eXposed surface, operatively attached to a ?rst surface of the 
adhesive layer; and a prodrug impermeable polymer ?lm on 
the eXposed surface of the prodrug layer and on a second 
surface of the adhesive layer. Alternatively, the prodrug 
layer and an opioid may be operatively attached to the ?rst 
surface of the adhesive layer. The substrate may be mam 
malian such as human skin. The prodrug may be a derivative 
of naltreXone, nalbuphine, nalorphine, naloXone, nalmefene, 
cyclaZocine, levallorphan, cyclorphan, oXilorphan, and 
pentaZocine, described infra Which are permeable through 
the dosage form and also permeable to the skin to Which the 
dosage form is applied. Alternatively, opioid(s) Which are 
permeable through the adhesive layer and are also perme 
able through the skin may be operatively attached to the 
adhesive layer. By the term “opioid” is meant any natural or 
synthetic opioid analgesic or other narcotic analgesic or 
mixtures thereof. Some eXamples of suitable opioids useful 
according to this invention are alfentanil, allylprodine, 
alphaprodine, anileridine, benZylmorphine, beZitramide, 
buprenorphine, butorphanol, clonitaZene, codeine, 
desomorphine, deXtromoramide, deZocine, diampromide, 
dihydrocodeine, dihydromorphine, dimenoXadol, 
dimepheptanol, dimethylthiambutene, dioXaphetyl butyrate, 
dipipanone, eptaZocine, ethoheptaZine, 
ethylmethylthiambutene, ethylmorphine, etonitaZene, 
fentanyl, hydrocodone, hydromorphone, hydroXypethidine, 
isomethadone, ketobemidone, levorphanol, lofentanil, 
meperidine, meptaZionl, metaZocine, methadone, metopon, 
morphine, myrophine, nalbuphine, narceine, nicomorphine, 
norlevorphanol, normethadone, normorphine, norpipanone, 
opium, oXycodone, oXymorphone, papaveretum, 
pentaZocine, phenadoXone, phenaZocine, phenoperidine, 
piminodine, piritramide, proheptaZine, promedol, 
properidine, propiram, propoXyphene, sufentanil, tilidine, 
fentanyl and pharmaceutically acceptable salts thereof and 
mixtures thereof. The most preferred opioids are fentanyl, 
buprenorphine, and pharmaceutically acceptable salts 
thereof. Alternatively, morphine derivatives that are perme 
able to the skin in analgetically effective amounts such as 
those disclosed by Bundgaard et al. in 1999, in US. Pat. No. 
5,908,846, herein incorporated by reference, may be opera 
tively attached to the ?rst surface 17 of the adhesive layer 
20. 
FIG. 1 illustrates a front cross-sectional vieW of a trans 
dermal drug delivery apparatus 1 on a substrate 5, in 
accordance With preferred embodiments of the present 
invention. The substrate 5 includes substrate material such 
as mammalian or human skin. The transdermal delivery 
apparatus 1 comprises: a prodrug permeable adhesive layer 
20, having a surface 3, formed on the substrate 5, Wherein 
the prodrug permeable adhesive layer 20 includes adhesive 
materials; a prodrug layer 15 formed on the surface 3 of the 
prodrug permeable adhesive layer 20, Wherein the prodrug 
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layer 15 has an exposed surface 23, and Wherein the prodrug 
layer 15 comprises prodrug materials that diffuse into the 
prodrug permeable adhesive layer 20, and a polymer ?lm 2, 
formed on the exposed surface 23 of the prodrug layer 15, 
Wherein the polymer ?lm may be made from materials that 
are impermeable to the prodrug. The adhesive layer 20 may 
be prepared from polymers and copolymers may be selected 
from the group consisting of, but not limited to, butyl 
acrylate, ethyl acrylate, ethyl hexyl acrylate, vinylacetate/ 
ethylene acrylate and mixtures thereof. The prodrug layer 15 
includes inter alia prodrug materials derived from an effec 
tive amount of opioid antagonists such as naltrexone, 
nalbuphine, nalorphine, naloxone, nalmefene, cyclaZocine, 
levallorphan, cyclorphan, oxilorphan, and pentaZocine, or 
combinations thereof. Alternatively, the prodrug layer 15 
may include a permeation enhancer material in addition to 
the prodrug material, Wherein the permeation enhancer 
material and the prodrug material are mixed to form a 
solution, suspension, gel or matrix having the effective 
amount of prodrug. The device may be any of the general 
types knoWn in the art including adhesive matrix and 
reservoir type transdermal delivery systems. The permeation 
enhancer material may include, but is not limited to, lauric 
acid, oleic acid, linoleic acid, octanol, decanol, lauryl 
alcohol, myristyl alcohol, myristoleyl alcohol, palmitoleyl 
alcohol, oleyl alcohol, linolenyl alcohol, linolyl alcohol, 
elaidyl alcohol, vaccenyl alcohol, petroselinyl alcohol, 
petroselaidyl alcohol, methyl caproate, propyl caproate, 
hexyl acetate, methyl heptylate, pentyl heptylate, heptyl 
acetate, heptyl caproate, methyl caprylate, propyl caprylate, 
octyl acetate, octyl butylate, methyl caprate, ethyl caprate, 
hexyl caprate, methyl pelargonate, butyl pelargonate, lauryl 
acetate, lauryl butylate, methyl laurate, ethyl laurate, iso 
propyl laurate, hexyl laurate, methyl myristate, ethyl 
myristate, isopropyl myristate, pentadecyl acetate, methyl 
palmitate, ethyl palmitate, isopropyl palmitate, hexadecyl 
acetate, methyl oleate, ethyl oleate, butyl oleate, dimethyl 
adipate, disopropyl adipate, disobutyl adioate, 
dimethylmaleate, diisopropyl malate, dibutyl malate, 
dihexyl maleate, ethyl alcohol and mixtures thereof. The 
polymer ?lm 2 may be made from materials including 
polyethylene, polypropylene, ethylene/propylene 
copolymers, ethylene/ethylacrylate copolymers, ethylene/ 
vinyl acetate copolymers, silicone elastomers, medical 
grade polydimethylsiloxanes, neoprene rubber, 
polyisobutylene, chlorinated polyethylene, polyvinyl 
chloride, vinylchloride-vinyl acetate copolymer, poly 
methacrylate polymer (hydrogel), polyvinylidene chloride, 
poly(ethylene terephthalate), butyl rubber, epichlorohydrin 
rubbers, ethylene-vinyl alcohol copolymer, ethyleneviny 
loxyethanol copolymer; silicone copolymers, polysiloxane 
polycarbonate copolymers, polysiloxane-polyethyleneoxide 
copolymers, polysiloxane-polymethacrylate copolymers, 
polysiloxane-polymethacrylate copolymers, polysiloxane 
alkylene copolymers polysiloxane-ethylene copolymers, 
polysiloxane-alkylenesilane copolymers, polysiloxaneethyl 
enesilane copolymers, cellulose polymers, methyl cellulose, 
ethyl cellulose, hydroxypropyl methyl cellulose, cellulose 
esters, polycarbonates, polytetra?uoroethylene, starches, 
gelatins, natural gums, synthetic gums, and combinations 
thereof. 
FIG. 2 depicts FIG. 1 after forming a prodrug imperme 
able barrier 25 betWeen the surface 3 of the prodrug per 
meable adhesive layer 20 and the prodrug impermeable 
polymer ?lm 2. The drug impermeable barrier 25 may be 
made from drug impermeable materials that include 
polyethylene, polypropylene, ethylene/propylene 
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copolymers, ethylene/ethylacrylate copolymers, ethylene/ 
vinyl acetate copolymers, silicone elastomers, medical 
grade polydimethylsiloxanes, neoprene rubber, 
polyisobutylene, chlorinated polyethylene, polyvinyl 
chloride, vinylchloride-vinyl acetate copolymer, poly 
methacrylate polymer (hydrogel), polyvinylidene chloride, 
poly(ethylene terephthalate), butyl rubber, epichlorohydrin 
rubbers, ethylene-vinyl alcohol copolymer, ethyleneviny 
loxyethanol copolymer; silicone copolymers, polysiloxane 
polycarbonate copolymers, polysiloxane-polyethyleneoxide 
copolymers, polysiloxane-polymethacrylate copolymers, 
polysiloxane-polymethacrylate copolymers, polysiloxane 
alkylene copolymers polysiloxane-ethylene copolymers, 
polysiloxane-alkylenesilane copolymers, polysiloxaneethyl 
enesilane copolymers, cellulose polymers, methyl cellulose, 
ethyl cellulose, hydroxypropyl methyl cellulose, cellulose 
esters, polycarbonates, polytetra?uoroethylene, starches, 
gelatins, natural gums, synthetic gums, and combinations 
thereof. Aprodrug layer 16 has been formed on a surface 19 
of a portion 13 of the prodrug permeable adhesive 20 and a 
prodrug layer 30 has been formed on a surface 17 of a 
remaining portion 14 of the prodrug permeable adhesive 
layer 20. The prodrug layers 16 and 30 include inter alia 
prodrug materials derived from an effective amount of 
opioid antagonists such as naltrexone, nalbuphine, 
nalorphine, naloxone, nalmefene, cyclaZocine, levallorphan, 
cyclorphan, oxilorphan, and pentaZocine or combinations 
thereof, described infra as prodrugs. Alternatively, 
effective amounts of opioid antagonists such as naltrexone, 
nalbuphine, nalorphine, naloxone, nalmefene, cyclaZocine, 
levallorphan, cyclorphan, oxilorphan, and pentaZocine or 
combinations thereof may be operatively attached to the ?rst 
surface 17 of the adhesive layer 20. Alternatively, the 
prodrug layers 16 and 30 may include a mixture containing 
a permeation enhancer material described supra and an 
effective amount of the prodrug material. Alternatively, 
opioid(s) Which, are permeable through the adhesive layer 
and are also permeable through the skin may be operatively 
attached to the ?rst surface 17 of the adhesive layer 20. 
Alternatively, morphine derivatives that are permeable to the 
skin in analgetically effective amounts such as those dis 
closed by Bundgaard et al. in US. Pat. No. 5,908,846, supra, 
may be operatively attached to the ?rst surface 17 of the 
adhesive layer 20. 
Another embodiment of the present invention is a method 
comprising the step of: transdermally delivering an effective 
amount of an opioid antagonist selected from the group 
consisting of naltrexone, nalbuphine, nalorphine, naloxone, 
nalmefene, cyclaZocine, Wherein the opioid antagonist is 
derived from a prodrug selected from the group consisting 
of, but not limited to naltrexone-R (I), nalbuphine-R,R1 (II), 
nalorphine-R,R1 (III), naloxone-R (IV), nalmefene-R (V), 
cyclaZocine-R (VI), having the, folloWing formulas: 
(I) 
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-continued 
(11) 
(III) 
(IV) 
(V) 
(VI) 
and wherein R and R1 are physiologically hydrolyZable and 
are selected from, but not limited to, alkylcarbonyl, 
arylcarbonyl, alkyloxycarbonyl, aryloxycarbonyl, 
carbamoyl, succinyl phosphate, pivalyl and combinations 
thereof. When either R or R1 include an alkylcarbonyl 
group, or When both include an alkylcarbonyl group, the 
alkylcarbonyl group further comprises acetyl, propionyl, 
valeroyl, pentanoyl, hexanoyl, heptanoyl, isobutyroyl, 
2-ethylbutryoyl and 2-propylpentanoyl and combinations 
thereof. When either R or R1 include an alkylcarbonyl 
group, or When both include a carbamoyl group, the car 
bamoyl group further comprises N,N-diethyl-amino 
carbamoyl, N-butyl-amino-carbamoyl, N,N-propyl-amino 
carbamoyl, N-hexyl-amino-carbamoyl, N-heptyl-amino 
carbamoyl and N-octyl-amino-carbamoyl and combinations 
thereof. 
Alternatively, the present invention is a method compris 
ing the step of: transdermally delivering an effective amount 
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of an opioid antagonist selected from the group consisting of 
levallorphan, cyclorphan, oxilorphan and pentaZocine 
Wherein substitution of a hydroxyl group in levallorphan has 
resulted in levallorphan-R (VII), in cyclorphan has resulted 
in cyclorphan-R (VIII), in oxilorphan has resulted in 
oxilorphan-R (IX), and in pentaZocine has resulted in 
pentaZocine-R (X), and Wherein R is physiologically hydro 
lyZable and has been selected from, but not limited to, 
alkylcarbonyl, arylcarbonyl, alkyloxycarbonyl, 
aryloxycarbonyl, carbamoyl, succinyl phosphate, pivalyl 
and combinations thereof. When R includes an alkylcarbo 
nyl group, the alkylcarbonyl group further comprises acetyl, 
propionyl, valeroyl, pentanoyl, hexanoyl, heptanoyl, 
isobutyroyl, 2-ethylbutryoyl and 2-propylpentanoyl and 
combinations thereof. When R includes a carbamoyl group, 
the carbamoyl group further comprises N,N-diethyl-amino 
carbamoyl, N-butyl-amino-carbamoyl, N,N-propyl-amino 
carbamoyl, N-hexyl-amino-carbamoyl, N-heptyl-amino 
carbamoyl and N-octyl-amino-carbamoyl and combinations 
thereof. 
Results 
Opioid antagonists such as naltrexone do not have the 
essential physicochemical properties that Would alloW an 
effective dose of the opioid antagonists to cross the human 
skin barrier. Hereinafter the term “physicochemical prop 
erty” means a property that includes both physical and 
chemical phenomena. The prodrugs of the present invention 
represented by chemical structures (I)—(VI) supra are more 
skin permeable and rapidly converted to their opioid antago 
nist analogues by physiological hydrolysis. 
The effect of transdermal delivery of the prodrug of 
structure (I), Wherein R is valeroyl (Val-NTX) is depicted in 
FIG. 3 and associated discussion under In Vitro Diffusion 
Studies in Example 1 infra. FIG. 3 depicts the accumulation 
in micrograms (ug) of naltrexone (NTX) in a receiver 
compartment of a diffusion cell When a saturated solution at 
32° C. of Val-NTX 50 or NTX 60 Was passed through human 
skin. NTX amounts Were measured at 6 hour intervals for 48 
hours. Further, FIG. 3 depicts about an eight-fold increase in 
the amount of NTX produced by physiological hydrolysis 
When the prodrug Val-NTX Was transdermally delivered 
through the skin sample into the receiver compartment of the 
diffusion cell compared to the amount of NTX delivered 
When naltrexone Was transdermally delivered through the 
skin sample. The data in FIG. 3 represent the meanione 
standard deviation of three cells With naltrexone in the donor 
compartment and four cells With Val-NTX prodrug in the 
donor compartment, using human skin from one individual. 
The lipophilic prodrugs such as Val-NTX and Hep-NTX 
provide a higher ?ux of naltrexone across the skin than 
naltrexone base (One-Way AN OVA, p<0.01). The Hep-NTX 
prodrug exhibits a trend toWards providing more ?ux 
enhancement than the Val-NTX prodrug, an eight-fold aver 
age increase in the ?ux enhancement ratio versus a four-fold 
average increase for Val-NTX. The ?ux enhancement ratios 
should not be limited to the 13:1 ratio in FIG. 4, but may be 
substantially greater. Table 1 infra lists the relative concen 
trations (umol/gram skin) of NTX, Wherein physiological 
hydrolysis of the prodrug having the chemical structure (I), 
supra, Wherein R is valeroyl (Val-NTX) or heptanoyl (Hep 
NTX) results from transdermal delivery of NTX through the 
skin. The mean molar percentage of regenerated naltrexone 
to total drug extracted from the skin Was about 31—38% for 
Val-NTX and Hep-NTX. 
US 6,569,449 B1 
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TABLE 1 
Relative Concentrations (‘umol/gram skin) of NTX:Prodrug From In 
Vitro Diffusion Studies. 
Drug Treatment NTX ,umol/g skin, (%) Prodrug ,umol/ g skin 
Val-NTX 
Hep-NTX 
0.651, 31 
1.426, 38 
1.08 
2.29 
Table 1 supra lists relative concentrations (,umol/gram skin) 
of NTXzprodrug from in vitro diffusion studies. Associated 
text in Example 1 under In Vitro Diffusion Studies describe 
calculation of a prodrug ?ux enhancement ratio (NTX ?ux 
from prodrug/NTX ?ux) for each subject’s sample of skin 
tested. Since human skin exhibits Wide inter-subject perme 
ation variability, this ?ux enhancement ratio is a good Way 
to compare the effect of the prodrug versus NTX, Within 
each individual skin sample. Using the method for calcu 
lating a mean ?ux enhancement ratio described infra in 
Example 1, the mean ?ux enhancement ratio for the Val 
NTX experiments is 4.4115 (one standard deviation), and 
an increased mean ?ux enhancement ratio of 8314.6 (one 
standard deviation) is calculated for the Hep-NTX data. 
Skin esterases are quite resistant to the stresses of freezing 
and storing, Which is Why prodrug is converted in the frozen 
skin experiments. In fact, the enzymatic stability studies 
Were done in previously frozen tissue samples, and a rapid 
enzymatic conversion rate Was observed in these experi 
ments. The rapid enzymatic conversion rate of the Val-NTX 
is a positive attribute for drug delivery, as the active drug 
Would be quickly released in the body after crossing the 
skin. 
The prodrugs’ melting points Were measured, as this 
physicochemical property is often easily related to the 
prodrugs’ solubilities (Stinchcomb et al., A Solubility and 
Related Physicochemical Property Comparison of 
Buprenorphine and its 3-alkyl Esters, Pharm. Res., 12, 
1526—1529 (1995). Hereinafter the term “physicochemical 
property” means a property that includes both physical and 
chemical phenomena. The doWnWard trend in melting points 
as a function of increasing alkyl chain length can be seen 
infra in Table 2. 
TABLE 2 
Molecular Weights (MW), and Melting Points (MP) of Naltrexone and 
its Ester Prodru_gs. 
Drug R-group MW MP (° C.) 
NTX —H 341 166-169 
VAL-NTX —CO(CH2)3CH3 425 83-85 
HEP-NTX —CO(CH2)5CH3 453 58-60 
Table 2 supra lists Val-NTX and Hep-NTX prodrug melting 
points, shoWing a decrease as the alkyl chain is extended, by 
over 100° C. in the case of the heptyl ester. The fact that the 
ester prodrugs exhibit loWer melting points than naltrexone 
base strongly suggests that the added alkyl functionalities 
disrupt the intra-crystalline cohesion of the drug. This crys 
tal destabilization can have a profound effect on solubilities. 
As expected, Table 2 supra lists the Val-NTX prodrug has a 
higher oil (nonpolar) solubility than the parent drug. 
Table 3 infra lists inter alia Val-NTX and Hep-NTX 
aqueous solubilities, Wherein the prodrugs exhibit much 
loWer aqueous solubilities than naltrexone base because of 
the prodrug’s lack of the free phenolic functional group, a 
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group that promotes aqueous solubility through hydrogen 
bonding. 
TABLE 3 
Physicochemical Properties of Naltrexone and Its Ester Prodrugs. 
Experimental Values ShoWn With Standard Deviations Are the Means 
of at Least TWo Determination 
Light Phosphate 
Mineral Buffer 
Oil Solubility 
Cal- Experi- Solubility pH 7.4 15‘ order 
culated“ mental 32° C., 32° C., 32° C., pH7.4 
Drug log Pb log Pb (mmol/L) (mmol/L) tl/2 (hr) 
NTX 0.36 0.67 r 0.258 r 15.2 1 No degradation 
0.02 0.012 1.6 seen in 10 days 
Val-NTX 1.95 1.77 r 9.62 r 0.593 r 96 r 10 
0.10 0.024 0.002 
Hep-NTX 3.01 Not Not 0.180 r 103 r 17 
available available 0.030 
“calculated from Daylight ® 4.51 SoftWare 
blog P = log octanol/Water partition coef?cient 
The octanol/Water partition coefficient increased logarithmi 
cally With the addition of the valeryl chain, as seen in Table 
3. 
Use of Daylight® 4.51 Software enabled calculation of 
log P (clogP) values for Naltrexone, and ester and carbamoyl 
prodrugs listed infra in Table 4. 
TABLE 4 
Calculated LOG P (clog P) of Naltrexone and Its Ester and 
Carbamovl Prodrugs. 
MW clogP 
Ester-R-group 
—H 341 .355 
—COCH3 383 .361 
—COCH2CH3 397 .890 
—COCH2CH2CH3 411 1.419 
—CO(CH2)3CH3 425 1.948 
—CO(CH2)4CH3 439 2.477 
—CO(CH2)5CH3 453 3.006 
—COCH2CH(CH3)2 425 1.821 
—COCH(CH2CH3)2 439 2.257 
—COCH(CH2CH2CH3)2 467 3.318 
Carbamate Ester-R-Group 
—CON(CH2CH3)2 440 1.36 
—CON(CH2)3CH3 440 1.67 
—CON(CH2CH2CH3)2 468 2.42 
—CON(CH2)5CH3 468 2.73 
—CON(CH2)6CH3 481 3.26 
—CON(CH2)7CH3 495 3.79 
“Calculated from Daylight ® 4.51 SoftWare. 
“Calculated log P (clog P) = log octanol/Water partition coe?icient. 
By using Daylight® 4.51 Software, one skilled in the art 
could calculate log P (clog P)=log octanol/Water partition 
coef?cient for prodrugs (I)—(X) Wherein R and R1 are 
physiologically hydrolyzable and are selected from, but not 
limited to, the group consisting of alkylcarbonyl, 
arylcarbonyl, alkyloxycarbonyl, aryloxycarbonyl and car 
bamoyl and combinations thereof, Without the need for 
further experimentation. In addition, Table 3 supra lists the 
log octanol/Water partition coef?cients for Val-NTX and 
Hep-NTX prodrugs, Wherein the log octanol/Water partition 
coef?cient is from about 1 to about 4. Based on the In Vitro 
Diffusion Studies described infra in Example 1, the data 
listed in Table 2 supra supporting the 8-fold ?ux enhance 
ment ratio When the source of the naltrexone Was Hep-NTX 
and the 4-fold ?ux enhancement ratio When the source of 
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naltrexone Was Val-NTX, and FIG. 3, supporting the 8-fold 
increased cumulative amount of naltrexone transdermally 
delivered through the skin, one skilled in the art could 
reasonably make and use the present invention to treat 
alcohol and narcotic dependence, according to the embodi 
ments of the present invention. 
Prodrug chemical stability to hydrolysis Was monitored in 
pH 7.4 phosphate buffer at 32° C. The prodrugs hydrolyZed 
in the buffer in an apparent ?rst-order fashion; therefore 
plots Were made of the natural logarithm of concentration 
depletion as a function of time. The observed half-lives 
calculated using the curves from these plots are summariZed 
infra in Table 1. The slopes of the curves, Which are equal 
to the rate constant, Were determined using linear regression 
analysis. None of the coef?cients of determination for the 
lines Were less than 0.95. The half-lives Were calculated by 
dividing 0.693 by the individual rate constants. All chro 
matograms from the degradation experiments shoWed an 
increasing naltrexone peak as the prodrug Was depleted. The 
prodrug hydrolysis reactions Were carried out to at least four 
half-lives. 
In Vitro Diffusion Studies 
In almost all cases, the prodrugs Were completely hydro 
lyZed on passing through the skin and appeared as naltrex 
one in the receiver compartment. Therefore, plots of the 
cumulative amounts of NTX permeated through human skin 
over time from saturated mineral oil solutions of either a 
prodrug or naltrexone base Were constructed for data analy 
sis. A representative NTX permeation pro?le is shoWn FIG. 
3. Steady-state ?uxes and lag times calculated using the 
terminal, linear regions of the curves are shoWn in FIGS. 3 
and 4, respectively. 
“Lag times” Which hereinafter mean the delay before 
detectable naltrexone appears in the receiver compartment 
of the diffusion cell due to physiological hydrolysis of 
Val-NTX or Hep-NTX are depicted in FIG. 4. The data 
represents the mean +/— one standard deviation of three cells 
With naltrexone in the donor compartment and four cells 
With saturated solutions of Val-NTX or Hep-NTX in the 
donor compartment, using human skin from one individual. 
The skin donor age, sex, and skin sample storage condition 
are shoWn for each experiment. F=female and M=male. 
Previously froZen skin samples (7—12 months) are indicated 
by frZ, and samples used fresh are indicated by frsh. *Iso 
tonic phosphate buffer, pH=7.4. **HEPES-buffered Hanks 
balanced salts solution. 
Example 1 infra describes in vitro diffusion studies With 
human skin using the prodrug material (I), Wherein R is a 
valeryl group (Val-NTX) and Wherein R is a heptanoyl 
group (Hep-NTX), to determine the level of opoid antago 
nist transdermal delivery enhancement. In Example 1, Val 
NTX and Hep-NTX are more skin permeable than naltrex 
one (NTX) and are rapidly converted to the respective 
opioid antagonist in the viable skin layers. 
EXAMPLE 1 
Naltrexone (NTX) base Was purchased from Mallinckrodt 
Inc., St. Louis, M0. The prodrug Were synthesiZed directly 
from naltrexone base. The drugs’ melting points Were mea 
sured on a hot-stage melting point apparatus (Fisher-Johns, 
Pittsburgh, Pa.). Reagent-grade chemicals Were obtained 
from Sigma Chemical Co. (St. Louis, Mo.). 
Prodrug Synthesis 
Val-NTX and Hep-NTX prodrug Material Were synthe 
siZed by dissolving naltrexone base (50 mg, 0.13 mmol) in 
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1 ml methylene chloride and triethylamine (50 ml, 0.7 
mmol). The solution Was placed in an ice bath and stirred. 
The acid chloride (0.15 mmol) of the desired prodrug 
moiety, or a solution thereof in methylene chloride, Was 
added dropWise. After addition Was complete, the reaction 
mixture Was alloWed to Warm up to room temperature and 
stirred for an additional 4 hrs. The progress of the reaction 
Was folloWed With thin layer chromatography (TLC): small 
samples (10 ml) of the reaction mixture Were spotted on 
silica gel plates and developed in an n-butanol:acetic acid: 
Water (10:1:1) cosolvent system. After drying, the plates 
Were sprayed With 10% HZSO4 in ethanol and heated at 100° 
C. for 5 min. NTX and its Prodrugs Were detected as broWn 
spots With typical Rf values (eg NTX=0.4 and Val-NTX= 
0.6). After completion of the reaction, the methylene chlo 
ride solution Was Washed With 10% aqueous sodium car 
bonate and then With Water, dried over anhydrous sodium 
sulfate, ?ltered, and reduced to a small volume on a rotary 
evaporator. The esters Were precipitated by adding excess 
petroleum ether and the desired product Was ?ltered off and 
dried on air. Purity Was checked by reversed-phase HPLC 
With UV-detection (230 nm) using a Water-acetonitrile gra 
dient (0—100% acetonitrile in 20 min.) on a C18 analytical 
column. If the purity Was less than 95%, the compounds 
Were further puri?ed by preparative HPLC. The ?nal prod 
ucts Were characteriZed by 1H-nuclear magnetic resonance 
spectroscopy (NMR, IBM FTNMR NR/250) and mass spec 
trometry. Val-NTX m/e Was 425.22. Hep-NTX m/e Was 
453.25. Val-NTX, 1H NMR (DMSO-d6): d 0.16—0.53 (m, 
5H, cyclopropyl), 0.96 (t, 3H, CH3), 1.3—3.4 (m, 20H, 
aliphatic), 4.85 (s, 1H, C-5) 6.31—6.62 (2d, 2H, aromatic); 
C25H31NO5. Hep-NTX, 1H NMR (DMSO-dG): d 0.19—0.47 
(m, 5H, cyclopropyl), 0.91 (t, 3H, CH3), 1.3—1.59 (m, 8H, 
aliphatic), 2.19—2.94 (m, 8H, aliphatic), 4.85 (s, 1H, C-5) 
6.31—6.62 (2d, 2H, aromatic); C27H35NO5. 
The HPLC system consisted of a Waters 717 
Autosampler, 501 Pumps, and a 484 Tunable UV Absor 
bance Detector With Millennium Chromatography SoftWare. 
A reversed phase 22-cm BroWnlee C-18 Spheri-5 micron 
column (and guard column) Were used With the UV detector 
set at a Wavelength of 215 nm. The mobile phase consisted 
of 0.1% tri?uoroacetic acid (adjusted to pH 3 With 
triethylamine): acetonitrile: sodium heptane sulfonate (300 
mL:700 mL:0.3 g) at a How rate of 1.5 mL/min. One 
hundred microliters of sample Were injected onto the col 
umn. Standard curves exhibited excellent linearity over the 
entire concentration range employed in the assays. The assay 
sensitivity Was 10 ng/mL. 
The prodrug materials Val-NTX and Hep-NTX Were 
isolated from the buffer samples by solid-phase extraction 
(Oasis HLB, Waters Corp., Milford, Mass.). The solid-phase 
extraction cartridge Was pretreated With one milliliter of 
methanol and one milliliter of Water before the aqueous drug 
sample Was run through the cartridge. After running the 
sample through the cartridge, the sample Was Washed With 
one milliliter of 5% methanol/Water, and eluted With aceto 
nitrile. Sample recovery Was ninety-eight percent. 
Octanol/Water Partition Coef?cients 
The octanol/Water partition coef?cients Were determined 
using pH 7.4 isotonic phosphate buffer as the aqueous phase. 
All steps Were carried out at room temperature. An appro 
priate amount of drug Was Weighed into a vial and dissolved 
in a knoWn amount of octanol. An equivalent amount of 
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buffer Was then added to the vial and the phases shaken for 
24 hours. The vials Were left undisturbed for at least one 
hour after shaking. An exact volume Was taken from the 
aqueous phase, diluted With acetonitrile, and then analyZed 
by HPLC. The ?nal pH of the aqueous phase at the end of 
the shaking period Was 7.95. Similarly, an exact volume Was 
taken from the octanol phase, diluted With acetonitrile, and 
then analyZed by HPLC. Partition coef?cients Were calcu 
lated by determining the phase concentration ratios. 
Solubilities 
The solubilities of naltrexone and its esters Were obtained 
by equilibrating large excesses of each substance With the 
respective vehicle, light mineral oil, or pH 7.4 isotonic 
phosphate buffer at 32° C. To hasten the attainment of 
equilibrium, each slurry Was continuously shaken in a sealed 
container in a shaking incubation oven. Samples Were taken, 
?ltered (mineral oil:Millex FG-13, Millipore and buffer 
:glass micro?ber, Gelman) above 32° C., measured With 
respect to volume, and diluted With the appropriate amount 
of acetonitrile. The diluted samples Were analyZed by 
HPLC. The initial forty percent of each ?ltrate Was dis 
carded to eliminate the possibility that adsorption of drug on 
the ?lter and/or the ?ltering apparatus might in?uence the 
solubility determination. The sampling procedure Was 
repeated at least once for each sample. Concentration versus 
time plots indicated that equilibrium Was obtained in less 
than 48 hours. Therefore, the equilibration times for all the 
studies Were 48 hours. 
Chemical Stability 
Solutions of the respective drug in pH 7.4 phosphate 
buffer Were monitored over time. The solutions Were stored 
in sealed vials in a 32° C. incubation oven. At appropriate 
time intervals, samples Were removed, isolated from the 
buffer by solid-phase extraction, and stored at 4° C. until 
HPLC quantitation. 
In Vitro Diffusion Studies 
The aim of in vitro experimentation in transdermal drug 
delivery is to quantitate the penetration of a drug molecule 
through the skin. Skin excised during abdominal reduction 
surgery from several patients Was used for the permeation 
studies. Skin samples Were sectioned from the excised 
abdominal tissue using a Padgett dermatome set to 250 pm; 
some skin samples Were frozen at —80° C., others Were used 
immediately. A PermeGear ?oW-through (In-Line, 
Riegelsville, Pa.) diffusion cell system Was used for the 
permeation studies. The receiver ?uid Was isotonic phos 
phate buffer at pH 7.4 in some experiments, and in more 
recent experiments We sWitched to a HEPES-buffered 
Hanks balanced salts solution, in order to help preserve 
tissue viability. The How rate of the receiver ?uid Was set at 
1 ml/hr in order to help maintain sink conditions. The drugs 
Were isolated from the receiver samples by solid-phase 
extraction, and stored at 4° C. until HPLC quantitation. The 
temperature of the diffusion cells Was maintained at 32° C. 
With a circulating Water bath. The diffusion experiment Was 
initiated by charging the donor compartment With 0.25 ml of 
drug suspended (saturated solution) in light mineral oil. 
The permeation data Were plotted as the cumulative amount 
of drug collected in the receiver compartment as a function 
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of time. The ?ux value for a given run Was calculated from 
Fick’s First LaW of diffusion, infra: 
Formula I: 
In this equation, J5 is the steady-state ?ux in g/cmZ/h; Ais the 
area of the membrane, 0.95 cm2; P is the effective perme 
ability coef?cient in cm/h; and AC is the concentration 
gradient across the membrane. Since build up in the receiver 
cell Was kept to a minimum throughout the studies, the latter 
is Well approximated by the donor concentration. 
Drug disposition in the diffusion cell skin samples Was 
measured at the end of the 48-hour experiment. The skin 
sample Was removed from the diffusion cell and rinsed With 
distilled Water, in order to remove the surface formulation. 
Further removal of the skin surface formulation Was accom 
plished by blotting With a paper toWel, and stripping With 
adhesive tape applied to the surface and quickly removed 
tWo times. The treated area of the skin Was cut from the skin 
sample and minced With a scalpel. The Wet tissue Weight Was 
recorded and the sample Was placed in a vial With ten 
milliliters of acetonitrile. The drug Was extracted from the 
tissue by sonicating the solution for ten minutes and shaking 
the vial overnight. The samples Were assayed by HPLC and 
reported as mmol of drug per gram of Wet tissue Weight. 
What is claimed is: 
1. A method for delivering an effective amount of an 
opioid antagonist selected from the group consisting of 
naltrexone, nalbuphine, nalorphine, naloxone, nalmefene, 
cyclaZocine, levallorphan, cyclorphan, oxilorphan and pen 
taZocine comprising transdermally administering an opioid 
antagonist prodrug selected from the group consisting of 
naltrexone-R (I), nalbuphine-R,R1 (II), nalorphine-R,R1 
(III), naloxone-R (IV), nalmefene-R (V), cyclaZocine-R 
(VI), levallorphan-R (VII), cyclorphan-R (VIII), 
oxilorphan-R (IX), and pentaZocine-R (X), 
Wherein R and R1 are physiologically hydrolyZable and are 
independently selected from the group consisting of 
alkylcarbonyl, arylcarbonyl, alkyloxycarbonyl, 
aryloxycarbonyl, phosphate and carbamoyl. 
2. The method of claim 1, Wherein transdermally deliv 
ering the prodrug results in a naltrexone ?ux enhancement 
ratio (?ux from prodrug:?ux from naltrexone) from about 
3:1 to about 13:1. 
3. The method of claim 1, Wherein the step of transder 
mally delivering further comprises applying the prodrug to 
an epidermal layer of human skin. 
4. The method of claim 1, Wherein the step of transder 
mally delivering further comprises applying the prodrug to 
an epidermal layer of animal skin. 
5. The method of claim 1, Wherein R and R1 include an 
alkylcarbonyl group selected from the group consisting of 
acetyl, propionyl, valeroyl, pentanoyl, hexanoyl, heptanoyl, 
isobutyroyl, pivalyl, succinyl, 2-ethylbutryoyl and 
2-propylpentanoyl and combinations thereof. 
6. The method of claim 1, Wherein R and R1 include a 
carbamoyl group selected from the group consisting of 
N,N-diethyl-amino-carbamoyl, N-butyl-amino-carbamoyl, 
N,N-propyl-amino-carbamoyl, N-hexyl-amino-carbamoyl, 
N-heptyl-amino-carbamoyl and N-octyl-amino-carbamoyl 
and combinations thereof. 
7. The method of claim 1, Wherein the step of transder 
mally delivering further comprises using a prodrug having a 
log octanol/Water partition coefficient from about 1 to about 
4. 
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8. The method of claim 1, wherein the step of transder 
mally delivering further comprises substantially physiologi 
cally hydrolyZing R and R1. 
9. The method of claim 7, Wherein the step of transder 
mally delivering further comprises substantially physiologi 
cally hydrolyZing R and R1. 
10. The method of claim 1 Wherein the prodrug is 
naltreXone-R, and Wherein R is an alkylcarbonyl group. 
11. The method of claim 10 Wherein the alkylcarbonyl 
group is valeroyl. 
12. The method of claim 10, Wherein the alkylcarbonyl is 
heptanoyl. 
13. A method for enhancing the delivery of an opioid 
antagonist through the skin of a patient comprising topically 
administering to the patient a prodrug of the opioid 
antagonist, Wherein the prodrug is selected from the group 
consisting of naltreXone-R (I), nalbuphine-R,R1 (II), 
nalorphine-R,R1 (Ill), naloXone-R (IV), nalmefene-R (V), 
cycloZocine-R (VI), levallorphan-R (VII), cyclorphan-R 
(VIII), oXilorphan-R (IX), and pentaZocine-R (X), 
Wherein R and R1 are physiologically hydroliZable and are 
independently selected from the group consisting of 
alkylcarbonyl, arylcarbonyl, alkyloXycarbonyl, 
aryloXycarbonyl, phosphate and carbamoyl. 
14. The method of claim 13 Wherein the prodrug is 
naltreXone-R. 
15. The method of claim 13 Wherein R is an alkylcarbo 
nyl. 
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16. The method of claim 14 Wherein the alkylcarbonyl is 
valeroly. 
17. The method of claim 14 Wherein the alkylcarbonyl is 
heptanoyl. 
18. A method of treating alcoholism or narcotic depen 
dence comprising topically administering to a patient an 
effective amount of a prodrug of an opioid antagonist, 
Wherein the prodrug is selected from the group consisting of 
naltreXone-R (I), nalbuphine-R,R1 (II), nalorphine-R,R1 
(III), naloXone-R (IV), nalmefene-R (V), cycloZocine-R 
(VI), levallorphan-R (VII), cyclorphan-R (VIII), 
oXilorphan-R (IX), and pentaZocine-R (X), 
Wherein R and R1 are physiologically hydroliZable and are 
independently selected from the group consisting of 
alkylcarbonyl, arylcarbonyl, alkyloXycarbonyl, 
aryloXycarbonyl, phosphate and carbamoyl and combina 
tions thereof. 
19. The method of claim 17 Wherein the prodrug is 
naltreXone-R. 
20. The method of claim 18 Wherein R is an alkylcarbo 
nyl. 
21. The method of claim 19 Wherein the alkylcarbonyl is 
valeroly. 
22. The method of claim 19 Wherein the alkylcarbonyl is 
heptanoyl. 
